New hope for tough brain cancers? early trial tests TG02 combo

NCT ID NCT03224104

First seen Dec 12, 2025 · Last updated May 04, 2026 · Updated 18 times

Summary

This early-phase study tested the drug TG02 in 71 patients with aggressive brain cancers (anaplastic astrocytoma or glioblastoma). It included older newly diagnosed patients and adults whose cancer had returned. The goal was to find the safest dose of TG02 when combined with either radiation or chemotherapy, and to see if it could help control the cancer for at least 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone

    Marseille, 13385, France

  • CHRU de Lille

    Lille, France

  • CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer

    Bron, 69677, France

  • Erasmus MC Cancer Institute - location Daniel den Hoed

    Rotterdam, 3015, Netherlands

  • Klinikum Der J.W. Goethe Universitaet-Klinik und Poliklinik fur Neurochirurgie

    Frankfurt, 60528, Germany

  • UniversitaetsSpital Zurich

    Zurich, 8091, Switzerland

  • Universitaetskliniken Regensburg - Universitaetsklinikum Regensburg

    Regensburg, 93053, Germany

  • Universitaetskliniken der Uni Wien - Universitaetsklinikum Wien - AKH uniklinieken

    Vienna, 1090, Austria

  • Universitaetsklinikum Bonn

    Bonn, 53205, Germany

  • Universitaetsklinikum Heidelberg - UniversitaetsKlinikum Heidelberg - Head Hospital

    Heidelberg, 69120, Germany

Conditions

Explore the condition pages connected to this study.